Tagged with Switzerland

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system, shares his M&A principles and insights, their exciting recent acquisition of DIFICLIR™ from Astellas, and the company’s recognition as a Great Place to Work® (GPTW) in Switzerland.   For…

Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…

Switzerland Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs. Although its approval times are increasing, raising doubts about Swissmedic’s continued place at the top table of global regulators, initiatives…

Switzerland Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up manufacturing capacity and scope, and why greater levels of both internal and external collaboration are crucial for the pharma industry…

Switzerland Clinerion, a leader in real-world data solutions, is helping bring medical data informatics to the life sciences industry. CEO Barış Erdoğan explains how the company is creating and applying technology to significantly reduce the drug development timeline. Clinerion uses Big Data analytics technologies to help hospitals, pharmaceutical companies and research…

Switzerland Pius Zängerle of curafutura, one of the two largest Swiss health insurers’ associations, explains the unique Swiss health insurance ecosystem and the main issues on his agenda for 2021 beyond the global pandemic.   As insurers, we want to see fair and affordable pricing, and we are willing to pay…

Switzerland A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head of Biogen’s Swiss affiliate and chair of the executive committee of industry association Interpharma, Gasser cites her diverse background as…

Switzerland Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with biosimilar portfolios. Chief Commercial Officer Anil Okay, who sits in Switzerland, explains the four company traits that he believes will…

Switzerland Professor Susan M. Gasser, now director and group leader emeritus of the Friedrich Miescher Institute for Biomedical Research (FMI), shares the crucial aspects behind the FMI’s world-class reputation in basic research, her thoughts on the importance of public-private collaboration, and her perspectives on the European research ecosystem. Since February 1,…

Switzerland Dr Chris Martin, CEO and co-founder of Swiss-headquartered antibody-drug conjugate cancer company, ADC Therapeutics, shares the company’s journey over the past decade, the exciting progress of their two lead candidates, the process of building their commercial organization in the US, and his perspectives on Big Pharma partnerships.   We have…

Switzerland Giorgio Calderari, the chairman of Farma Industria Ticino, the association of chemical and pharmaceutical industries in the Swiss canton of Ticino, explains how a region with a population of 350,000 has managed to create a turnover of over two billion dollars, excelling as an innovative hub. Furthermore, he analyzes the…

Switzerland The CEO & President of CDMO CordenPharma, Dr Michael Quirmbach, delves into the contract manufacturing industry, explaining the reasons behind the recent commercial success of his organization, including their partnership with Moderna, and his view on the new processes and technology shaping the industry.   A CDMO does not really…